Skip to content

    Pacira BioSciences (PCRX) stock price & financials

    View PCRX earnings calls

    Overview

    Price

    Market Cap

    Sector

    Rank

    Performance1.4% 1Y

    Financials

    Income Statement

    Financial Trajectories

    11
    Quarterly
    MetricQ3 FY24Q4 FY24Q1 FY25Q2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Trend
    EarningsRevenue
    $168.57M
    $187.25M
    $168.92M
    $181.10M
    $179.52M
    +6.5%
    $196.87M
    +5.1%
    $177.38M
    +5.0%
    $192.40M
    +6.2%
    Strengthening
    Operating Profit
    -$139.53M
    $24.70M
    $1.99M
    $8.50M
    $6.36M
    $2.34M
    -90.5%
    $6.90M
    +246.8%
    $4.27M
    -49.8%
    Strengthening
    Net Profit
    -$143.47M
    $16.04M
    $4.81M
    -$4.85M
    $5.43M
    $1.64M
    -89.8%
    $2.92M
    -39.4%
    $4.65M
    Weakening
    EPS
    $-3.11
    $0.10
    $-0.11
    $0.12
    $0.07
    -30.0%
    $0.12
    Weakening
    Other Income
    $671.0K
    $822.0K
    $6.72M
    -$10.43M
    $3.16M
    +371.2%
    -$1.77M
    -315.2%
    -$1.90M
    -128.4%
    -$1.71M
    +83.6%
    Weakening
    Interest
    $4.69M
    $4.68M
    $4.58M
    $4.70M
    $4.28M
    -8.7%
    $3.89M
    -16.8%
    $3.70M
    -19.2%
    $3.62M
    -22.9%
    Weakening
    Depreciation
    Profit before Tax
    -$138.86M
    $25.53M
    $8.71M
    -$1.93M
    $9.52M
    $571.0K
    -97.8%
    $5.00M
    -42.6%
    $2.56M
    Weakening
    MarginsOPM
    -82.8%
    13.2%
    1.2%
    4.7%
    3.5%
    1.2%
    -91.0%
    3.9%
    +229.7%
    2.2%
    -52.7%
    Strengthening
    Tax
    -3.3%
    37.2%
    44.7%
    -151.5%
    43.0%
    -186.7%
    -602.4%
    41.7%
    -6.9%
    -82.1%
    +45.8%
    Weakening
    ReturnsROIC
    74.8%
    -8.4%
    -2.5%
    2.5%
    -2.8%
    -103.8%
    -0.9%
    +89.8%
    -1.5%
    +39.4%
    -2.4%
    -196.0%
    Weakening

    Balance Sheet

    Balance Sheet

    USD · Annual
    Line itemFY18FY19FY20FY21FY22FY23FY24FY25TTM
    AssetsCash & Equivalents$132.53M$78.23M$99.96M$585.58M$104.14M$153.30M$276.77M$158.54M$205.88M
    Short-Term Investments
    Total Current Assets$477.97M$408.56M$651.62M$866.05M$498.33M$509.99M$745.13M$547.97M$615.22M
    Net PP&E$108.67M$142.81M$211.18M$264.81M$254.39M$234.95M$216.39M$182.47M$175.20M
    Goodwill$62.04M$99.55M$99.55M$145.20M$163.24M$163.24M$0$20.21M$19.64M
    Intangibles$0$104.39M$96.52M$623.97M$540.55M$483.26M$425.97M$368.10M$285.48M
    Total Assets$689.35M$831.07M$1.27B$2.08B$1.68B$1.57B$1.55B$1.26B$1.24B
    LiabilitiesTotal Current Liabilities$60.66M$107.67M$253.33M$521.12M$147.77M$97.38M$309.92M$120.59M$122.01M
    Short-Term Debt$201.78M$0
    Long-Term Debt$689.47M$522.44M$383.55M$372.19M$363.12M
    Long-Term Leases$0$40.94M$71.03M$71.73M$64.80M$54.81M$44.65M$36.18M$38.70M
    Total Liabilities$368.13M$476.12M$654.83M$1.34B$906.19M$704.26M$775.17M$571.81M$572.00M
    EquityCommon Stock & APIC$41.0K$42.0K$44.0K$45.0K$46.0K$46.0K$47.0K$48.0K$49.0K
    Retained Earnings-$388.23M-$399.40M-$253.88M-$211.90M-$148.75M-$106.80M-$206.36M-$199.32M-$191.75M
    Total Equity$321.23M$354.94M$619.69M$730.41M$775.01M$870.13M$778.35M$693.11M$671.98M
    HighlightsNet Cash / (Debt)-$308.55M-$213.64M

    Cash Flow

    Cash Flow

    USD · Annual
    Line itemFY18FY19FY20FY21FY22FY23FY24FY25TTM
    ActivitiesCash from Operating$48.87M$70.52M$77.03M$125.72M$145.27M$154.65M$189.39M$151.99M$187.66M
    Cash from Investing$20.58M-$128.49M-$277.61M-$20.79M-$225.19M$77.54M-$83.28M$99.48M$94.15M
    Cash from Financing$8.95M$3.67M$222.30M$380.69M-$401.53M-$183.03M$17.36M-$369.63M-$376.18M
    SummaryCapital Expenditure-$14.51M-$10.16M-$37.80M-$45.87M-$30.08M-$15.16M-$10.64M-$15.33M-$8.15M
    Free Cash Flow$34.36M$60.36M$39.23M$79.85M$115.20M$139.49M$178.75M$136.66M$179.51M
    FCF Margin10.2%14.3%9.1%14.7%17.3%20.7%25.5%18.8%24.1%

    Ratios